In summary, our in vivo studies demonstrate that inhibition of lp-PLA2 by darapladib does not decrease dyslipidemia but ameliorates the inflammatory burden, resulting in decrease of atherosclerosis in high-fat diet-fed ApoE-deficient mice. This evidence concerns the gene APOE and metabolic syndrome.